103.87
Schlusskurs vom Vortag:
$104.85
Offen:
$105.7
24-Stunden-Volumen:
1.18M
Relative Volume:
0.42
Marktkapitalisierung:
$17.27B
Einnahmen:
$381.03M
Nettoeinkommen (Verlust:
$-1.01B
KGV:
-17.46
EPS:
-5.95
Netto-Cashflow:
$-789.25M
1W Leistung:
+4.41%
1M Leistung:
+53.78%
6M Leistung:
+46.95%
1J Leistung:
+50.55%
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
INSM
Insmed Inc
|
104.03 | 17.27B | 381.03M | -1.01B | -789.25M | -5.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
520.04 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
318.31 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.12 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
261.40 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-13 | Eingeleitet | Jefferies | Buy |
2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-04-23 | Eingeleitet | Truist | Buy |
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
2023-07-26 | Eingeleitet | Guggenheim | Buy |
2022-12-09 | Eingeleitet | Mizuho | Buy |
2022-12-07 | Eingeleitet | Barclays | Overweight |
2022-11-18 | Eingeleitet | BofA Securities | Buy |
2022-04-27 | Eingeleitet | Goldman | Buy |
2021-12-06 | Eingeleitet | JP Morgan | Overweight |
2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2020-12-17 | Eingeleitet | Berenberg | Buy |
2020-10-12 | Fortgesetzt | Stifel | Buy |
2019-09-03 | Eingeleitet | Goldman | Buy |
2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2018-07-23 | Eingeleitet | Goldman | Neutral |
2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
2017-09-05 | Bestätigt | Evercore ISI | Outperform |
2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
2016-03-15 | Eingeleitet | Stifel | Buy |
2015-11-09 | Herabstufung | UBS | Buy → Neutral |
2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
2015-06-09 | Eingeleitet | Citigroup | Neutral |
2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insider Sell: Roger Adsett Sells 10,686 Shares of Insmed Inc (INSM) - GuruFocus
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110 - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 - Insider Monkey
Is Insmed Stock Overvalued at $98? - Nasdaq
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating - Insider Monkey
Insmed Completes $750 Million Follow-On Public Offering - Global Legal Chronicle
Is Insmed Stock Overvalued After The 45% Jump? - Forbes
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
Insmed Inc (INSM) Soars 30% on Impressive Study - MSN
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results - Insider Monkey
INSM September 19th Options Begin Trading - Nasdaq
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - Yahoo Finance
Insmed (INSM) Soars After Raising $650 million - MSN
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
SEC Form 424B5 filed by Insmed Incorporated - Quantisnow
Insmed prices capital raise of $750 via stock offering - MSN
Insmed announces $650M public offering of common stock - MSN
Insmed Stock Ends Volatile Session Lower, Pauses After Monumental 32% Weekly Surge - Daily Chhattisgarh News
Insmed aims to raise $750M in one of the largest stock offerings this year - Endpoints News
Stocks To Watch: Insmed Sees RS Rating Jump To 93 - MSN
Insmed dips after $750 mln stock sale - TradingView
Insmed (INSM) Secures $750 Million Through Stock Offering - GuruFocus
Insmed is an attractive, but expensive takeout meal - statnews.com
INSM Increases Common Stock Offering to $750M | INSM Stock News - GuruFocus
Insmed Prices $750 Million Common Stock Offering - MarketScreener
Bank of America Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - Defense World
Insmed Raises Massive $750M in Stock Offering to Advance Breakthrough Drug Pipeline - Stock Titan
INSM: Mizuho Raises Price Target for Insmed to $110 | INSM Stock News - GuruFocus
Insmed Prices Public Offering Of About 7.81 Mln Shares At $96.00/shr - Nasdaq
Insmed raises $750 million in public offering of common stock By Investing.com - Investing.com Canada
Insmed Announces Pricing of $750 Million Public Offering of Comm - GuruFocus
Insmed raises $750 million in public offering of common stock - Investing.com
Insmed Announces Pricing Of $750 Million Public Offering Of Common Stock At $96 Per Share - marketscreener.com
Insmed Announces Pricing of $750 Million Public Offering of Common Stock - marketscreener.com
These 10 Stocks Are Flying High - Insider Monkey
Insmed (INSM) Plans $650M Public Offering of Common Stock | INSM - GuruFocus
Insmed's drug for rare lung disease meets main goal in mid-stage trial - MSN
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM) - Yahoo Finance
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Benzinga
Insmed (INSM) Sees Price Target Boost Amid Strong PAH Data | INS - GuruFocus
Insmed (INSM) Price Target Raised to $120 by HC Wainwright & Co. - GuruFocus
Insmed (INSM) Plans $650M Stock Offering, Shares Fall - GuruFocus
Insmed announces $650 million public offering of common stock - Investing.com
Insmed announces $650 million public offering of common stock By Investing.com - Investing.com Canada
Insmed Plans $650 Million Public Offering - marketscreener.com
Insmed announces $650M common stock offering - TipRanks
Insmed Announces Proposed $650 Million Public Offering of Common Stock | INSM Stock News - GuruFocus
Insmed (INSM) Sees Boost with Positive Phase 2b Trial Results | - GuruFocus
Insmed (INSM) Receives Boosted Price Target from Wells Fargo | I - GuruFocus
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Bonstein Sara | Chief Financial Officer |
Jun 23 '25 |
Sale |
101.78 |
57,765 |
5,879,089 |
93,536 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):